Skip to main content
Equibles
EW logo

EW · Edwards Lifesciences Corp

Track EW — free

Use EW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$107.15 +1.35 (+1.28%) At close · Nov 13
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$61.61B
Shares
575.00M
Volume · Nov 13 3.82M Avg daily vol (3M) 3.81M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$107.15 Open$106.11 Day$106.01–107.69 52W close$75.87–107.15 Avg vol 30d4.6M Short int9.4M · 1.6% of shares · 2.8d Short vol57% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Next earnings call
Feb 9, 2027 Est · unconfirmed · in 12 wks
Q2 2026 earnings call transcript
call held Jul 23, 2026
Play latest call

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sales rise 13.5% as impairment weighs on earnings

Edwards Lifesciences Corp reported first nine months of 2026 net sales of $5,105.1 million, up 13.5%, while a $220.2 million impairment and 31.2% effective tax rate contributed to lower diluted earnings per share.

Revenue $1.72B ▲ 10.5% Net income $307.5M ▲ 5.6% Diluted EPS $0.53 ▲ 6.0%
Read from the MD&A section
4 source passages
Total net sales | 1,715.5 | 1,553.1 | 162.4 | 10.5% | 5,105.1 | 4,498.0 | 607.1 | 13.5% Intangible and long-lived assets impairment charges of $220.2 million during the three and nine months ended September 30, 2026 were primarily related to the full impairment of a certain in-process research and development asset. Our effective income tax rate attributable to continuing operations was 17.0% and 16.1% for the three months ended September 30, 2026 and 2025, respectively and 31.2% and 16.1% for the nine months ended September 30, 2026 and 2025, respectively. The decrease in our diluted earnings per share in the nine months ended September 30, 2026, was driven primarily by an increase in our tax expense and certain impairment charges, partially offset by our aforementioned operational performance. Open the document at this passage
Nov 4
Current report 8-K
Third-quarter growth drives higher 2026 sales and EPS guidance

Edwards Lifesciences reported Q3 2026 sales of $1.72 billion, up 10.5%, and raised full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97 to $3.05.

Financial results
5 source passages
IRVINE, CA, November 4, 2026 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% 2026 Outlook Increasing total company sales2 growth guidance to approximately 11.5% from 10% to 11% Increasing adjusted EPS guidance to $2.97 to $3.05 from $2.95 to $3.05, growing 18% at midpoint versus prior year Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.74B ▲ 13.6% Net income $241.9M ▼ 27.4% Diluted EPS $0.42 ▼ 25.0%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.67B
Trailing 12 months
Net income (TTM)
$1.02B
Trailing 12 months
Revenue growth YoY
+10.5%
Year over year
Operating margin
21.6%
Trailing 12 months
P / E (TTM)
60.5
Trailing earnings · reciprocal yield 1.7%
FCF yield
2.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.4%
Year over year · fewer shares
Price change (1Y)
+24.4%
Trailing year
Short interest
1.6%
Latest settlement · 2.8 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲9.4% $1.39B $385.60M '24 Q4 ▲6.2% $1.41B $358.00M '25 Q1 ▲11.9% $1.53B $333.20M '25 Q2 ▲14.7% $1.55B $291.10M '25 Q3 ▲13.3% $1.57B $91.20M '25 Q4* ▲16.7% $1.65B $380.70M '26 Q1 ▲13.6% $1.74B $241.90M '26 Q2 LATEST ▲10.5% $1.72B $307.50M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Low
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +18%
above
RSI (14) 80
overbought
MACD trend Positive
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +24%
trailing
6-month return +22%
trailing
YTD return +26%
this year
Relative strength +22%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $90 › 200d $86 — 50d above 200d
Institutional flow Accumulating
1,221 of 1,347 funds reported for Sep 30 · net +6.2M sh shares · +90 new
Insider flow Distributing
Net -$3.3M over 90 days · 100% sells
Short interest Rising
1.63% of shares out · ▲ +0.5% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,347 holders — near 3-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Strong
Revenue growth +12%
Y/Y
Gross margin 78%
contracting
EPS growth −74%
Y/Y
Free cash flow $1.3B
Valuation P/E 60.5
rich
Buyback $1.5B
remaining
Quant / Vol
risk profile
Low
Volatility 26%
annualized · 1-yr
Max drawdown −13%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 8
Latest guidance · from the Earnings Call filed Jul 23, 2026
Total company sales · full year 2026 Raised $6.6B – $6.9B
Apr 23, 2026 $6.5B – $6.9B changed to Jul 23, 2026 $6.6B – $6.9B
prior FY $6.07B midpoint +11.2% Y/Y
TAVR sales growth · full year 2026 8% – 9%
TMTT sales · full year 2026 Raised $760M – $780M
Apr 23, 2026 $740M – $780M changed to Jul 23, 2026 $760M – $780M
Adjusted EPS · full year 2026 Non-GAAP Maintained $2.95 – $3.05
Apr 23, 2026 $2.95 – $3.05 changed to Jul 23, 2026 $2.95 – $3.05
Total company sales growth · full year 2026 10% – 11%
TAVR sales growth · full year 2026 8% – 9%
R&D expense as a percentage of sales · full year 2026 Maintained 17%
Apr 23, 2026 17% changed to Jul 23, 2026 17%
Previous outlook earlier release · from the 8-K filed Apr 23, 2026

Still-open targets the latest release did not restate under the same label.

Gross profit margin · full-year 2026 78% – 79%
Operating profit margin · full-year 2026 28% – 29%
Prior guidance period ended · from the Earnings Call filed Jul 23, 2026
Sales · Q3 2026 $1.63B – $1.71B
Adjusted EPS · Q3 2026 $0.71 – $0.77
Guided vs delivered · last 8 settled
Sales Q3 2026
guided $1.63B – $1.71B
$1.72B Beat +2.7%
Total sales Q2 2026
guided $1.66B – $1.74B
$1.74B Beat +2.4%
Sales first quarter 2026
guided $1.55B – $1.63B
$1.65B Beat +3.7%
Total sales fourth quarter of 2025
guided $1.51B – $1.59B
$1.57B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+18% Bullish
RSI (14)
80 Bearish
MACD trend
Positive Bullish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $90 › 200d $86 — 50d above 200d
Institutional flow Accumulating
1,221 of 1,347 funds reported for Sep 30 · net +6.2M sh shares · +90 new
Insider flow Distributing
Net -$3.3M over 90 days · 100% sells
Short interest Rising
1.63% of shares out · ▲ +0.5% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,347 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $76 Now $107 · 100% Range high $107
vs 200-day avg +24% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EW
Edwards Lifesciences Corp
this stock
$61.61B +25.7% +11.5% 60.5 1.6%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1,371
% held
92.4%
Reported
1,221 of 1,347
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
911
View
Short & Settlement
Short Interest Rising
Shares short
9.4M
Days to cover
2.8d
Change
+48.8K sh
View
Short Volume
Short vol %
57%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
18
Value
$1.5K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
42.3%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.3M
Buyers / Sellers
0 / 4
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$6.1B
Net income (FY)
$1.1B
EPS diluted
$1.83
View
Buybacks
Remaining
$1.5B
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
18

Edwards Lifesciences reported Q3 2026 sales of $1.72 billion, up 10.5%, and raised full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97 to $3.05.

View
Proposed Sales
Value
$193.6K
Shares
1.9K
Filed
Nov 10, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 4, 2026
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Edwards Lifesciences Reports Thir…
Published
Nov 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
EW +4.9% +23.7% +22.4% +16.5% +25.7%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +2.3% +24.9% +21.9% +16.6% +15.1%

Capital returns

Buyback program · as of Jul 23, 2026
Authorized
—
Spent (derived)
—
Remaining
$1.50B

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1099800 CUSIP 28176E108 13F (30d) 1090 filings 1004 filers Visit website Investor relations